Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy in Patients With Acute Myeloid Leukemia Who Had Relapsed/Refractory Disease or Positive Minimal Residual Disease

NCT05362942 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT05362942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05362942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy in Patients With Acute Myeloid Leukemia Who Had Relapsed/Refractory Disease or Positive Minimal Residual Disease
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 1, 2022
Completion date
April 30, 2024
Enrollment
52 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease, refractory acute myeloid leukemia, relapsed acute myeloid leukemia